Personalized medicine uses information about a person's genes, proteins, and cellular environment to prevent, diagnose, and treat disease. At NewYork-Presbyterian/Columbia University Medical Center the advent of personalized medicine is changing how we treat patients by employing targeted treatment strategies based on a tumor's specific molecular characteristics. Many tumors have unique pathologic and molecular characteristics that may warrant different treatment strategies. With these targeted therapies, our team can develop treatment strategies with greater specificity, at the same time helping patients avoid side effects from treatments that may be less-than-optimal for their tumor type.
The Columbia University Thoracic Oncology team is leading the nation in developing less invasive methods to diagnose and biopsy tissue for analysis prior to full treatment utilizing proteomic analyses, gene expression analyses, and chromosomal abnormalities analyses. These tests also enable us to guide our patients toward clinical trials and new drugs that my be tailored to the patient and the genetic analysis of the tumor. Some presently open clinical trials can be searched on our Herbert Irving Comprehensieve Cancer Center webpage: http://www.hiccc.columbia.edu/clinical-trials/